Business Today
Loading...

Govt may cap FDI in pharma at 49%

Fearing uncontrolled mergers and acquisitions by foreign drug firms that could lead to further increase in drug prices and also cartelisation, the government is eyeing capping the 100 per cent foreign direct investment (FDI) currently allowed through automatic route in the pharma sector at 49 per cent and that too through the government route.

Sanjay Singh | September 6, 2010 | Updated 12:05 IST

Fearing uncontrolled mergers and acquisitions (M&As) by foreign drug firms that could lead to further increase in drug prices and also cartelisation, the government is eyeing capping the 100 per cent foreign direct investment (FDI) currently allowed through automatic route in the pharma sector at 49 per cent and that too through the government route.

The finance ministry as well as the Planning Commission have advised the concerned ministries to expedite the process to ensure that 65 per cent of Indians, who according to the World Health Organisation (WHO) still lack access to essential medicines, are not deprived of affordable and high- quality medicines.

Earlier this year, Piramal Healthcare sold its domestic formulations business to US based Abbot for `17,353 crore.

This is the second- biggest acquisition of an Indian drug firm, after the country's largest drug maker Ranbaxy was acquired by Japan's Daiichi Sankyo for ` 21,574 crore in 2008.

Concerned that acquisition of Indian pharma firms by multinational corporations (MNCs) was impacting the availability of low-cost medicines, the commerce and industry ministry, which formulates FDI norms had proposed tightening the rules so that Indian acquisitions by MNCs flow through it and not through the automatic route.

It had also mooted the idea of offering licenses to domestic firms to produce patented drugs to protect consumers' interests.

The commerce ministry has also come out with a discussion paper on " Compulsory Licensing" - a system whereby a third party other than the patent holder is allowed to produce and market a patented product or process - for formulating a coherent and concerted approach. The discussion paper seeks views from all stakeholders by this month- end.

Several developed and developing countries have introduced compulsory licensing. But these licenses under WTO norms have not taken off in India yet due to the absence of manufacturing facilities. Currently, a large part of the cancer drugs sold in India are patented and manufactured by MNCs such as Novartis, GSK and Roche, which cost over a lakh for a month- long treatment making these drugs unaffordable for the Indian population.

The paper also points at legal provisions and other related aspects of patent laws in India. It suggests the introduction of a compulsory licensing system to put a check on spiralling drug prices. It has also suggested measures to make available affordable drugs within the ambit of the National Pharmaceutical Pricing Authority ( NPPA) by expanding the number of drugs from its current scrutiny of pricing of 74 drugs. Another option could be by invoking the Competition Act, 2002.

The health ministry has also objected to lobbying by global drugmakers to change India's intellectual property rules.

The Prime Minister's Office ( PMO) had circulated a note based on views by global drugmakers that seeks changes such as legislative review of India's patent laws, data exclusivity and implementation of patent linkages.

If implemented, the proposals can have a huge bearing on the grant of patents in India, affecting the cost of treatment.

The FDI shield pill

The Commerce ministry has suggested that FDI levels in the sector through automatic route should be cut from 100% to 49%, meaning all proposals for foreign investment above 49% would need FIPB approval

Why India?

India has some of the lowest drug prices in the world thanks to an earlier policy of not following stringent patent protection rules as prevalent in the West

This spawned an entire industry of local drugmakers, which thrived by making copycat versions of expensive, patent- protected medicines by adopting a different manufacturing process

India now ranks third in terms of volume of production ( 9.3% of global share) and 14th in terms of value ( 1.5% of global share)

India's ` 35,175 crore ($ 7.5 bn) drug industry is among the world's top- five bulk drugs producers

India's bio- tech industry clocked a 17% growth with revenues of $ 3 bn in 2009- 10 over the previous fiscal

It is also among the world's 20 top pharmaceutical exporters, with exports growing at 17.8% per year

Bio- pharma was the biggest contributor generating 60% of the industry's growth at ` 8,829 crore

Fear from MNC rise

Market share of MNC drugmakers in the local retail drug mkt has surged to 25% from 15% in 2007 and experts predict this will grow to 50% in next 5 years

Experts feel if India does not take care, its domestic industry could be gobbled up by drug MNCs and the generic industry could be wiped out

Public health experts say there are fewer local companies to challenge the patents of ' global innovators companies'

  • Print
  • COMMENT
BT-Story-Page-B.gif
A    A   A
close